Device Trial Radar · NCT06149000
Migraine Headache Mitigation Utilizing Avulux
Last checked: Nov 19, 2026Latest source record: Nov 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 13, 2023
Primary completion
Jun 13, 2024
Study completion Jun 20, 2024
Sponsor
- Lead sponsor
- Kaiser PermanenteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 28, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This will be a randomized double blind cross over interventional trial to determine if Avulux lenses are able to reduce headache symptoms in patients
Conditions
- Migraine
- Headache
- Photophobia
Interventions
Avulux LensesDevice
Avulux lenses are specialized eyewear designed to reduce specific wavelengths of light to alleviate symptoms in individuals who experience light sensitivity and migraines
Placebo LensesDevice
Lenses that will look identical to Avulux lenses without the medical benefits
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction in migraine frequencyTime frame: 6 months
- Reduction in migraine severityTime frame: 6 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.